Doublet Treatment of Chordoma Cells with Anti–PD-L1 (N-601) and Anti-EGFR (Cetuximab) Antibodies Further Enhances Sensitivity to Lysis by IL15 Superagonist (N-803)-activated NK Cells. This evidence concerns the gene IL15 and chordoma.